Tempest CAR-T Trial Data Bolsters 2026 Registrational Study Plans
Event summary
- Interim results from Tempest's REDEEM-1 Phase 1/2a trial of TPST-2003 showed a 100% complete response (CR) rate among six evaluable patients.
- A prior investigator-initiated trial (IIT) demonstrated a median progression-free survival (PFS) of 23.1 months, including patients with extramedullary disease.
- 36 patients with relapsed/refractory multiple myeloma (rrMM) have been treated across two studies as of February 25, 2026.
- Tempest plans to submit a U.S. Investigational New Drug (IND) application and initiate a registrational study in 2026, contingent on clearance.
The big picture
Tempest's early data for TPST-2003 represents a potentially significant advancement in CAR-T therapy for relapsed/refractory multiple myeloma, a market with a substantial unmet need and significant commercial potential. The dual-targeting approach aims to address a key limitation of current therapies – antigen escape – and could position TPST-2003 as a best-in-class option. However, the success hinges on replicating these initial findings in larger trials and securing regulatory approval, a process that carries inherent risks and timelines.
What we're watching
- Regulatory Pathway
- The FDA’s response to Tempest’s planned IND submission will be critical, as it will dictate the timeline and potential design of the registrational study and influence investor sentiment.
- Data Replication
- Whether the observed efficacy and safety profile can be consistently replicated across the remaining patients in the REDEEM-1 trial and in a larger, controlled registrational study will be key to validating TPST-2003’s potential.
- Competitive Landscape
- The success of TPST-2003 will depend on its ability to demonstrate a meaningful advantage over existing CAR-T therapies, particularly in terms of durability of response and safety profile, given the increasing competition in the rrMM treatment space.
Related topics